Login to Your Account



After Second Rejection, AMT Halts Glybera Development

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, October 26, 2011

Amsterdam Molecular Therapeutics (AMT) NV's bid to become the first Western biotechnology firm to gain a gene therapy approval suffered a second rebuff, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) stood over its original negative opinion on a marketing authorization application for Glybera (alipogene tiparvovec), which is in development for the ultra-rare indication lipoprotein lipase deficiency.

Shares in the company (AMSTERDAM:AMT) plunged 51 percent when the news was disclosed Friday, to close at €0.38 (US$0.43).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription